Skip to main content
OpenTrials
Completed

NCT Number: NCT06702137

EXOPULSE Mollii Suit, Motor Function & Multiple Sclerosis

Spasticity is a frequent and debilitating symptom in patients with multiple sclerosis (MS). It can alter the patients' balance, mobility, as well as their quality of life. The available therapeutic strategies for treating spasticity and related symptoms are usually faced with limited efficacy and numerous side effects.

For these reasons, non invasive stimulation techniques, namely transcutaneous stimulation by means of EXOPULSE Mollii suit, might be of help in this context.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Multiple Sclerosis Autoimmune Diseases Autoimmune Diseases of the Nervous System Demyelinating Autoimmune Diseases, CNS Demyelinating Diseases Immune System Diseases Muscle Hypertonia Muscle Spasticity Muscular Diseases Musculoskeletal Diseases Nervous System Diseases Neurologic Manifestations Neuromuscular Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Clinical Neurophysiology Department, Henri Mondor Hospital

Créteil, VAL DE MARNE, 94000, France

About this study

The investigators designed a randomized crossover, sham-controlled, double blind trial to demonstrate the improvement of motor functions and MS related symptoms following a single session of "active" versus "sham" EXOPULSE Mollii suit. A 2-week washout period should be enough to prevent a potential carry over effect. Two weeks after the end of this phase (phase 1), a second phase of this trial, an open label phase, will be proposed for all patients to understand the effects of EXOPULSE Mollii suit employed over four weeks (a session every other day for a total of 14 sessions) on MS related symptoms.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Definite MS diagnosis according to the 2017 McDonald criteria since at least one month.
  • Age between 18 and 75 years.
  • Ability to walk freely or with the need of support (expanded disability status scale score (EDSS) < 7).
  • Being free of relapses in the last three months.
  • Being French speaker, able to understand verbal instructions, and affiliated to the national health insurance (sécurité sociale).
  • Having spasticity with a score of at least 1+ on the MAS.
  • Having a BBS score ≤46 associated in the literature with a risk of fall

Exclusion criteria

  • Being included in another research protocol during the study period.
  • Inability to undergo medical monitoring for the study purposes due to geographical or social reasons.
  • Having a cardiac stimulator, a ventriculoperitoneal shunt, an intrathecal baclofen pump or other contraindications to using EXOPULSE Mollii suit.
  • Being pregnant.
  • Having a change in their pharmacological therapy in the last three months.
  • Suffering from other somatic or neuropsychiatric diagnoses (e.g., arrhythmias, uncontrolled epilepsy, diseases causing osteoarticular and muscular pain).
  • Having a body mass index above 35 Kg/m2.
  • In case of the introduction of a medical device other than EXOPULSE Mollii suit during the study period
  • Patients under juridical protection (" mesure de protection judiciare : tutelle, curatelle, sauvegarde de justice ")
  • Prisoners.

Treatment and study plan

EXOPULSE MOLLII SUIT (active)

Device

This study aims to evaluate the effects of the EXOPULSE Mollii suit, a non-invasive assistive device that delivers transcutaneous electrostimulation. The suit includes a CE-labeled class IIa control unit and class I body garments. Equipped with 58 electrodes, the full-body suit stimulates various muscle groups to reduce spasticity by activating antagonistic muscles through reciprocal inhibition, rather than causing muscle contractions. Designed to relax spastic muscles, improve range of motion, prevent atrophy, enhance circulation, and provide pain relief, the device is easy to use, requiring only one hour of daily wear, with effects lasting over 24 hours.

Current treatments for spasticity, such as botulinum toxin and oral medications, have limitations like side effects and minimal mobility improvement. The EXOPULSE Mollii suit offers an innovative alternative, with early studies indicating positive impacts on mobility and motor function.

EXOPULSE MOLLII SUIT (sham)

Device

In the sham condition, the control unit will be programmed to start stimulating for 1 minute then it will shut off.

Primary outcomes

  1. Improvement in balance using the BBS (Berg Balance Scale) )

    Time frame: BBS will be evaluated at Day 1 (before & after the intervention, phase 1) and at Day 15 (before & after the intervention, phase 1)

    Balance will be assessed using the 14-item Berg Balance Scale (BBS) which has good psychometric properties in PwMS (concurrent validity, interrater reliability). The scale rates the balance using 56 points, with higher scores indicating better balance abilities. A score equal to or below 45 is commonly associated with the risk of falls across the literature.

Secondary outcomes

  1. Assessment of the cumulative effects of EXOPULSE Mollii suit on balance using the BBS (Berg Balance Scale) after 4 weeks of using Exopulse Molii Suit

    Time frame: BBS evaluation will occur at Day 30 (before phase 2) and at Day 60 (at the end of phase 2)

    BBS has good psychometric properties in PwMS (concurrent validity, interrater reliability). The scale rates the balance using 56 points, with higher scores indicating better balance abilities. A score equal to or below 45 is commonly associated with fall risk across the literature.

  2. Assessment of the spasticity using the MAS (Modified Ashworth Scale)

    Time frame: Spasticity according to MAS will be assessed through study completion at Day 1 (before and after the intervention, phase 1), at Day 15 (before and after the intervention, phase 1), at Day 30 (before phase 2) and at Day 60 (at the end of phase 2)

    Spasticity will be evaluated by examiners using the MAS (Modified Ashworth Scale)

  3. Assessment of the spasticity using the VAS spasticity (Visual Analogue Scale)

    Time frame: VAS spasicity will be assessed through study completion at Day 1 (before and after the intervention, phase 1), at Day 15 (before and after the intervention, phase 1), at Day 30 (before phase 2) and at Day 60 (at the end of phase 2)

    Spasticity will be evaluated by patients using a VAS (Visual Analogue Scale)

  4. Mobility will be assessed using the TUG (Time Up and Go)

    Time frame: Mobility according to TUG will be assessed through study completion at Day 1 (before and after the intervention, phase 1), at Day 15 (before and after the intervention, phase 1), at Day 30 (before phase 2) and at Day 60 (at the end of phase 2)

    The TUG is a validated test that assesses walking in PwMS (Bennett et al., 2017). The score is expressed as the time (in seconds) required to perform sequential motor tasks (standing up from the chair, walking to the line on the floor at a normal pace, turning, walking back to the chair at a normal pace, and finally sitting down).

  5. Mobility will be assessed using the FES-I (Falls Efficacy Scale-International scale)

    Time frame: FES-I will be assessed at Day 30 (before phase 2) and at Day 60 (at the end of phase 2)

    Subjective risk of fall will be assessed using the French version of the Falls Efficacy Scale-International scale (FES-I) ; a 14-item scale that assesses the perceived risk of falling.

  6. Mobility will be assessed using the MSWS-12 (Multiple Sclerosis Walking Scale - 12)

    Time frame: MSWS-12 will be assessed at Day 30 (before phase 2) and at Day 60 (at the end of phase 2)

    Subjective changes in walking would be evaluated by the Multiple Sclerosis Walking Scale - 12 (MSWS-12), a 12-item scale that examines the impact of MS on walking capacity, is a validated patient-reported measure for exploring this outcome.

  7. Quality of life will be measured using the MusiQoL (Multiple Sclerosis International Quality of Life Questionnaire)

    Time frame: MusiQOL will be assessed at Day 30 (before phase 2) and at Day 60 (at the end of phase 2)

    This variable will be measured using the 31-item Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL), which has good psychometric properties and yields a total score and subscores for nine dimensions: activity of daily living, psychological well-being, symptoms, friends' relationships, family relationships, satisfaction with health care, sentimental and sexual life, coping and rejection.

  8. Pain will be assessed using a VAS (Visual Analogue Scale)

    Time frame: Pain according to VAS will be assessed through study completion at Day 1 (before and after the intervention, phase 1), at Day 15 (before and after the intervention, phase 1), at Day 30 (before phase 2) and at Day 60 (at the end of phase 2)

    VAS is a 10 mm straight horizontal line with one end meaning no pain and the other end meaning the worst pain imaginable

  9. Fatigue will be assessed using a VAS (Visual Analogue Scale)

    Time frame: Fatigue according to VAS be assessed through study completion at Day 1 (before and after the intervention, phase 1), at Day 15 (before and after the intervention, phase 1), at Day 30 (before phase 2) and at Day 60 (at the end of phase 2)

    VAS is a 10 mm straight horizontal line with one end meaning no fatigue and the other end meaning extreme fatigue

  10. Evaluation of overall improvement using the CGI (Clinical Global Impression)

    Time frame: CGI will be assessed at Day 1 (after the intervention, phase 1), at Day 15 (after the intervention, phase 1) and at Day 60 (at the end of phase 2)

    It consists of 7-point scale ranging from "very much improved since the initiation of treatment" to "very much worse since the initiation of treatment" (from 1 to 7)

  11. Evaluation of patient's blinding to the type of stimulation in the crossover trial

    Time frame: Blinding wil be assessed at Day 1 (after the intervention) and at Day 15 (after the intervention) during Phase 1.

    This blind evaluation will be done in phase 1 using a dedicated questionnaire (only for each treatment condition, since all patients will receive the same active treatment in open phase 2).

Sponsors and collaborators

Lead sponsor

Institut De La Colonne Vertebrale Et Des Neurosciences

Other

Registry information

Official study title

The Effects of EXOPULSE Mollii Suit on Motor Functions in Patients With Multiple Sclerosis (EXOSEP Study)

Acronym: EXOSEP

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Nov 22, 2024
Registry last updated
Jun 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.